Natera, INC Form 4 insider transactions

Director Roelof Botha exercised stock options of Natera, Inc. on March 15, 2024, resulting in the acquisition and disposal of common stock.

Natera's CEO, Steven Leonard Chapman, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Sheena, co-founder of Natera, Inc., reports gifting shares of common stock and shares held in trust for minor children.

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on March 5th and 6th, 2024, to cover tax obligations and under a pre-arranged Rule 10b5-1 trading plan.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports selling 2,160 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Natera CEO Steven Chapman sold 9,326 shares of common stock on March 5, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Natera's CFO, Michael Brophy, sold 2,826 shares of common stock on March 5, 2024, to satisfy tax obligations related to vesting Restricted Stock Units.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reports the acquisition and disposal of company stock related to RSU vesting and tax obligations.

John Fesko, President and Chief Business Officer of Natera, Inc., sold shares to cover tax obligations following the vesting of restricted stock units.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., sold shares of common stock on March 5, 2024, to cover tax obligations and under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Sheena, co-founder of Natera, Inc., reports the sale of common stock and acquisition of Restricted Stock Units (RSUs) through recent transactions.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., reports the acquisition of 4,104 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports acquiring 2,160 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs) on March 1, 2024.

Natera's CEO, Steven Leonard Chapman, reports acquiring 9,326 shares of common stock through fully-vested Restricted Stock Units (RSUs) on March 1, 2024.

Natera's CFO, Michael Brophy, reports acquiring 2,826 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs) on March 1, 2024.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reported acquiring 2,329 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs) on March 1, 2024.

John Fesko, President and Chief Business Officer of Natera, Inc., reports acquiring 2,400 shares of common stock through the issuance of fully-vested Restricted Stock Units (RSUs).

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., exercised stock options and sold shares of common stock on February 27 and 29, 2024, according to a Form 4 filing with the SEC.